Generic Tivicay (Dolutegravir)

Dolutegravir is the active ingredient in Tivicay®, an HIV integrase inhibitor used with other antiretrovirals to treat HIV-1. Generic dolutegravir contains the same active ingredient at the same strengths and is produced by licensed pharmaceutical manufacturers, typically far below the originator price. Used as prescribed by a licensed medical professional.

Tivicay® is the originator brand for dolutegravir, developed by ViiV Healthcare. It is prescribed, in combination with other antiretroviral medicines, for the treatment of HIV-1 infection in adults and children. It is a prescription-only medicine used under medical supervision.

Dolutegravir is an integrase strand transfer inhibitor (INSTI). It blocks the integrase enzyme that HIV uses to insert its genetic material into human cells, helping to reduce the amount of virus in the body. It is always used as part of a combination regimen directed by your doctor.

Dolutegravir is prescribed for adults and children living with HIV-1, as part of combination antiretroviral therapy determined by an HIV specialist.

Dolutegravir is usually taken once daily (some situations require twice daily), with or without food, as part of a combination regimen. Certain antacids, calcium, iron, and some other medicines need to be spaced apart from your dose. Consistent daily dosing is important for it to work and to reduce resistance.

Never change your dose on your own.

Reported side effects of dolutegravir may include headache, difficulty sleeping, nausea, and tiredness. Tell your doctor if you are or may become pregnant, and about all medicines and supplements you take, as timing or choice may need adjusting. This is not a complete list.

Report new or worsening symptoms to your doctor promptly. This is not a complete list — see the patient information leaflet.

Store as directed on the patient information leaflet, usually at room temperature away from moisture and out of reach of children. Always follow the storage guidance supplied with your medicine.

The Tivicay price reflects branded pricing from its originator, ViiV Healthcare, together with marketing costs and the patent protection that limits who may sell dolutegravir in higher-income markets. That is why the brand can cost around $1,800 a month in the United States and roughly £400 a month in the United Kingdom. Generic dolutegravir contains the identical active ingredient at the same 10 mg, 25 mg and 50 mg strengths, but is produced by licensed pharmaceutical manufacturers — frequently under voluntary licensing arrangements — without those brand overheads, which is why it is available at a substantially lower cost.

The saving comes from manufacturing and licensing economics, not from any change to the medicine inside the tablet. Dolutegravir is a prescription-only integrase inhibitor taken alongside other antiretrovirals, so whether you use the brand or a generic, it must be prescribed and monitored by a doctor experienced in HIV care and taken exactly as directed.

Generic dolutegravir is consistently priced far below branded Tivicay — the wide availability of generics is what has made long-term HIV treatment more affordable across much of the world. It contains the same active ingredient at the same 10 mg, 25 mg and 50 mg strengths as the brand, so what changes is the price, not the medicine inside the tablet.

There is no single fixed figure, because the final price depends on the strength, the quantity in the pack and the delivery destination — see the individual product pages for current pricing. Dolutegravir is prescription-only and is used as part of a combination regimen, so a valid prescription and your clinician's guidance are required before ordering.

All three products are built around the same integrase inhibitor, dolutegravir, but they are packaged differently. Tivicay supplies dolutegravir on its own, to be combined with other antiretrovirals chosen by your clinician. Triumeq is a three-drug single tablet that pairs dolutegravir with abacavir and lamivudine, while Dovato is a streamlined two-drug single tablet of dolutegravir and lamivudine. Fewer separate tablets can simplify a daily routine, but the number of drugs in a regimen is a clinical decision based on resistance testing, co-infections and individual factors — not a matter of price.

If you are comparing options, our generic Triumeq and generic Dovato pages explain those fixed-dose combinations in detail. Whichever regimen applies to you, dolutegravir manages HIV as a long-term condition rather than curing it, and any change between regimens must be prescribed and reviewed by an HIV specialist.